Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
First Lines: July 2021 publishersweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publishersweekly.com Daily Mail and Mail on Sunday newspapers.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Relief Reports 2020 Financial Results and Provides Business Update
April 15, 2021 GMT
GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update.
“The past year has been an incredibly productive and rewarding one for all of us at Relief,” said Raghuram (Ram) Selvaraju, Chairman of the Board. “We have had an opportunity to make a true difference in fighting the ongoing COVID-19 pandemic with the development of RLF-100(TM) to treat critically ill patients. With the goal of bringing this potential treatment to patients as expeditiously as possible, we en
Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. The past year has been an incredibly productive and rewarding one for all of us at Relief, said
Raghuram (Ram) Selvaraju, Chairman of the Board. We have had an opportunity to make a true difference in fighting the ongoing COVID-19 pandemic with the development of RLF-100 to treat critically ill patients. With the goal of bringing this potential treatment to patients as expeditiously as possible, we entered into important partnerships and made key hires, adding executives to our team who have strong expertise in important areas such as clinical development, regulatory and commercialization.